David A. Six

VenatoRx Pharmaceuticals (United States)

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Fluorescent sensors of siderophores produced by bacterial pathogens”.

Fluorescent sensors of siderophores produced by bacterial pathogens

Journal of Biological Chemistry(2022)10.1016/j.jbc.2022.101651

N/A

0DataRank · unranked

30 citations

Taihao Yang, Somnath Chakravorty, Aritri Majumdar, Brittany L. Nairn, David A. Six +9 more

Examining the activity of cefepime-taniborbactam against Burkholderia cepacia complex and Burkholderia gladioli isolated from cystic fibrosis patients in the United States

Antimicrobial Agents and Chemotherapy(2023)10.1128/aac.00498-23

N/A

0DataRank · unranked

6 citations

Elise T. Zeiser, Scott A. Becka, John J. LiPuma, David A. Six, Greg Moeck +2 more

Cefepime–taniborbactam activity against antimicrobial-resistant clinical isolates of Enterobacterales and Pseudomonas aeruginosa: GEARS global surveillance programme 2018–22

Journal of Antimicrobial Chemotherapy(2024)10.1093/jac/dkae329

N/A

0DataRank · unranked

24 citations

Mark G. Wise, Meredith Hackel, David A. Six, Tsuyoshi Uehara, Denis M. Daigle +4 more

ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam combined with cefepime

Antimicrobial Agents and Chemotherapy(2024)10.1128/aac.00751-24

N/A

0DataRank · unranked

14 citations

Ayman M. Abdelhamed, Caryn E. Good, Andrew R Mack, Christopher R. Bethel, Steven H. Marshall +12 more

ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten

Antimicrobial Agents and Chemotherapy(2024)10.1128/aac.01127-24

N/A

0DataRank · unranked

6 citations

Caryn E. Good, Ayman M. Abdelhamed, Andrew R Mack, Christopher R. Bethel, Steven H. Marshall +12 more

Structure and mechanism of taniborbactam inhibition of the cefepime-hydrolyzing, partial R2-loop deletion Pseudomonas -derived cephalosporinase variant PDC-88

Antimicrobial Agents and Chemotherapy(2025)10.1128/aac.00078-25

N/A

0DataRank · unranked

2 citations

Vijay Kumar, Christopher R. Bethel, Magdalena A. Taracila, Brittany Miller, Tsuyoshi Uehara +5 more

Burkholderia pseudomallei PenI β-lactamase and variants are potently inhibited by taniborbactam

Antimicrobial Agents and Chemotherapy(2025)10.1128/aac.00787-25

N/A

0DataRank · unranked

0 citations

Scott A. Becka, Mitchell Edwards, Cullen L. Myers, Kyoko Uehara, Tsuyoshi Uehara +8 more

ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate β-lactamase inhibitor ledaborbactam combined with ceftibuten.

UNC Libraries(2025)10.17615/tde0-ye85

N/A

0DataRank · unranked

0 citations

Vance G. Fowler, Daniel D. Rhoads, Andrea M. Hujer, Robert A Bonomo, Christopher R. Bethel +12 more